The Federal Bio-Technology Transfer Directory includes descriptions of hundreds of federal inventions and technologies/products in the marketplace, being developed by licensees, or being developed through CRADAs.

Technologies that have been licensed and where federal labs have a dominant or leading patent position include:

* cancer therapeutics and diagnostics using diverse approaches;

* infectious disease therapeutics and diagnostics, including viral infections, malaria, new and emerging pathogens, chlamydia, pneumocystis pneumonia, Legionnaire's disease, listeria, pertussis and others;

* gene therapy, including retroviral gene therapy vectors now in clinical trials for treatment of various diseases, and adenovirus, papillomavirus and other second generation gene therapy vectors in development;

* antisense agents, including the broad class of antisense phosphorothioate oligonucleotides, with drugs from various companies in clinical trials and more in development;

* amorphous cyclodextrins for drug solubilization and delivery systems;

* cell and chromosome sorters, cytometers and imaging systems;

* glucocerebrosidase, both the recombinant enzyme approved for treatment of Gaucher's disease and the gene in clinical trials for gene therapy treatment of the disease;

* gene sequencing, including fundamental technologies;

* magainin peptides for treatment of bacterial infections;

* vaccines, including various new approaches for epitope design and selection, vaccine carriers, vaccinia virus and other vaccine vectors, liposomes and adjuvants;

* screening assays for identifying potential therapeutics in a number of disease areas;

* water soluble dietary oat fiber (Oatrim) used in various specialty food products;

* transforming growth factor-beta and other wound healing agents in clinical trials by several companies;

* imitation human milk from cow's milk;

* primate and other animal models for various diseases;

* monoclonal antibodies and hybridomas, many used for immunodiagnostics and research reagents;

* cholinesterase inhibitors with unique properties being developed for treatment of cocaine addiction, Alzheimer's disease and other neurological disorders;

* non-opioid and morphine analogs approved for analgesic use and synthetic methods;

* methods for direct administration of monoclonal antibodies and recombinant proteins into the lungs;

* various cytokines, lymphokines and growth factors;

* protein and macromolecule crystallization apparatus;

* radiopharmaceuticals, radioimmune conjugation methods, boron neutron capture therapy, radiolabeled red blood cells and various medical radioisotopes;

* radioimaging and radiotherapy methods and apparatus;

* chromosome paints and imaging methods and reagents;

* biosensors for drug, alcohol and other screening uses;

* bioreactors, including organoid culture apparatus and widely used capillary bioreactors;

* prosthetic devices for handicapped persons and amputees;

* electromagnetic body and organ heating apparatus for hypothermia, frostbite and cancer treatments;

* thermoacoustic cooling engines with no moving parts for cooling life science experiments;

* nitric oxide-releasing agents and prodrugs for hypertension and other therapeutic uses;

* silver stains, widely used for chromatographic and electrophoretic visualization of proteins and nucleic acids;

* liver cell lines for study of hepatitis, screening potential therapeutics and vaccine production;

* cis-retinoic acids for treatment of acne;

* erbB-3 and other oncogenes being used to develop cancer therapeutics, immunotoxins, diagnostics and for screening potential therapeutics;

* cytochrome p450 clones for carcinogenesis study and in vitro carcinogenicity testing;

* adoptive immunotherapy methods for cancer treatment, including use of lymphokine activated killer (LAK) cells and tumor infiltrating lymphocytes (TIL);

* T-cell activated antigen (Tac) antibodies used for immunotoxins and diagnostics for tissue rejection and cancer treatment;

* multidrug resistance (MDR1) genes for screening cancer treatments to avoid development of resistance and as selectable markers for gene therapy;

* transforming growth factor-beta in clinical trials for treatment of eye lens disorders and other wound healing uses;

* chelating and protein conjugation methods and reagents widely used for production of radiopharmaceuticals, immunotoxins and other conjugates;

* keratinocyte growth factors for cancer and psoriasis treatment, diagnosis and screening potential therapeutics;

* Peptide T in clinical trials for treatment of psoriasis;

* restriction endonucleases used as lab reagents;

* hole detection and condom testing methods;

* ovarian tumor antibodies used in radioimmune conjugates in clinical trials and immunotoxins in development;

* platelet-derived growth factor receptor genes for treatment, diagnosis and screening potential treatments for a variety of diseases;

* trimetrexate approved for treatment of pneumocystis pneumonia;

* fludarabine (F-araA) approved for cancer treatment;

* platinum complexes used for cancer treatment;

* primate care, feeding and other apparatus;

* prosthetic urethral valves used for incontinence treatment;

* implantable fiber optic O2, hydrogen and other sensors;

* surgical catheters, stents and shunts;

* commonly used glass water distillation flasks;

* coil planet and counter-current separation apparatus; and

* blood cell separation apparatus.